...
首页> 外文期刊>The Pediatric infectious disease journal >Immunogenicity and reactogenicity of a combined adsorbed tetanus toxoid, low dose diphtheria toxoid, five component acellular pertussis and inactivated polio vaccine in six-year-old children.
【24h】

Immunogenicity and reactogenicity of a combined adsorbed tetanus toxoid, low dose diphtheria toxoid, five component acellular pertussis and inactivated polio vaccine in six-year-old children.

机译:六岁儿童中破伤风类毒素,低剂量白喉类毒素,五组分脱细胞百日咳和灭活脊髓灰质炎疫苗的联合免疫原性和反应原性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: The objective of this study was to assess the immunogenicity and reactogenicity of the combined adsorbed tetanus toxoid, low dose diphtheria toxoid, 5-component acellular pertussis and inactivated polio vaccine (TdcP-IPV) as compared with a pediatric dose diphtheria formulation, combined with adsorbed tetanus toxoid and 3-component acellular pertussis (DTacP), in 6-year-old children who were immunized with 4 doses of diphtheria-tetanus-whole cell cellular pertussis (DTwcP) plus oral polio vaccine (OPV) before 2 years of age, according to the local Spanish vaccination calendar. METHODS: One hundred ninety-four healthy 6-year-old children were randomized to receive 1 dose of TdcP-IPV or 1 dose of DTacP and OPV. RESULTS: One month postvaccination, antidiphtheria and antitetanus titers were > or =0.1 IU/mL in 100% of patients in both study groups. TdcP-IPV reached 100% seroprotection rates against polio types 1, 2 and 3. In OPV recipients, these rates were 100, 100 and 96.8%, respectively. Seropositivity rates for pertussis toxin, filamentous hemagglutinin, pertactin and fimbrial components of the TdcP-IPV vaccine were 97.9, 89.6, 90.6 and 100%. The incidence of local and systemic reactions was 50.5 and 39.2% in the TdcP-IPV group and 59.4 and 38.5% in the DTacP plus OPV group, and no serious adverse events were reported. CONCLUSIONS: TdcP-IPV vaccine was shown to be immunogenic and safe when given as a booster in children 6 years of age who were primed with 4 doses of DTwcP and OPV.
机译:背景:这项研究的目的是评估与破伤风小儿白喉制剂联合使用的破伤风类毒素,低剂量白喉类毒素,5组分无细胞百日咳和灭活脊髓灰质炎疫苗(TdcP-IPV)联合使用的免疫原性和反应原性在6岁的儿童中,使用破伤风类毒素和3组分无细胞百日咳杆菌(DTacP)进行吸附,在2年前用4剂白喉-破伤风-全细胞细胞百日咳(DTwcP)和口服脊髓灰质炎疫苗(OPV)进行了免疫根据西班牙当地的疫苗接种日历确定年龄。方法:将194例健康的6岁儿童随机接受1剂TdcP-IPV或1剂DTacP和OPV。结果:两个研究组中100%的患者在接种疫苗后一个月,抗白喉和抗破伤风的效价≥0.1 IU / mL。 TdcP-IPV对1型,2型和3型小儿麻痹症的血清保护率达到100%。在OPV接受者中,分别为100%,100%和96.8%。 TdcP-IPV疫苗的百日咳毒素,丝状血凝素,百日咳杆菌粘附素和纤维成分的血清阳性率分别为97.9、89.6、90.6和100%。 TdcP-IPV组的局部和全身反应的发生率分别为50.5和39.2%,DTacP加OPV组的发生率为59.4和38.5%,未报告严重不良事件。结论:TdcP-IPV疫苗在6岁的儿童中以4剂DTwcP和OPV初次接种时,具有免疫原性和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号